REVIEW
Add like
Add dislike
Add to saved papers

Intralesional corticosteroid treatment of multiple eruptive keratoacanthomas: case report and review of a controversial therapy.

BACKGROUND: Use of intralesional corticosteroids in the management of keratoacanthomas has been reported in older literature. Yet this therapy is no longer a commonly considered treatment option.

OBJECTIVE: To report management of a therapeutically challenging patient with multiple eruptive keratoacanthomas with intralesional corticosteriod treatment to revive awareness of this treatment option.

METHODS: A 55-year-old female with frequent episodes of multiple eruptive keratoacanthomas was treated with intralesional corticosteroids and methotrexate.

RESULTS: Intralesional corticosteroids successfully treated eruptive keratoacanthomas with complete regression and minimal scarring within 2-4 weeks.

CONCLUSION: Despite its limitations, intralesional corticosteroids may have a role in the treatment of select keratoacanthomas.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app